Anemia of Chronic Disease

Anemia of chronic disease—now often called anemia of inflammation—is anemia that develops in the setting of infection, chronic inflammation, malignancy, or other conditions that activate the immune system. It is typically mild to moderate and is driven largely by inflammation-induced restriction of iron supply to the marrow.

Definition

Anemia of chronic disease is a hypoproliferative anemia arising from immune activation, in which inflammatory cytokines and the hormone hepcidin restrict iron availability for erythropoiesis, blunt the erythropoietin response, and shorten red-cell survival.

Scope

This entry covers anemia of chronic disease as a clinical entity: its inflammatory mechanism, the central role of the iron-regulatory hormone hepcidin, its usual laboratory picture (normocytic or mildly microcytic with low serum iron but normal or raised stores), and how it is distinguished from and may coexist with iron-deficiency anemia. It is reference material, not clinical guidance, and contains no dosing or individualized treatment advice.

Core questions

• How does inflammation reduce iron availability to developing red cells?
• What is the role of hepcidin in trapping iron within macrophages and reducing absorption?
• How can anemia of chronic disease be distinguished from—or recognized alongside—iron-deficiency anemia?

Key concepts

• Inflammation and immune activation
• Hepcidin and ferroportin
• Functional iron restriction (low serum iron, normal/high ferritin)
• Blunted erythropoietin response
• Reduced red-cell survival
• Normocytic-to-microcytic morphology
• Coexistent iron deficiency

Mechanisms

Immune activation raises inflammatory cytokines that induce hepatic hepcidin. Hepcidin binds the iron exporter ferroportin and triggers its degradation, so iron is held inside macrophages and intestinal absorption falls (Nemeth et al., 2004). The result is functional iron restriction: serum iron is low while iron stores (ferritin) are normal or elevated, and the marrow cannot obtain enough iron despite adequate total body iron. Inflammation also blunts the marrow's response to erythropoietin and modestly shortens red-cell survival. Together these produce a usually mild, hypoproliferative anemia that is most often normocytic and can become mildly microcytic; when true iron deficiency is superimposed, distinguishing markers such as soluble transferrin receptor and hepcidin become useful (Weiss & Goodnough, 2005; Theurl et al., 2009; Ganz, 2019).

Clinical relevance

Anemia of chronic disease is one of the most common anemias in hospitalized and chronically ill people, so recognizing its inflammatory, hepcidin-mediated pattern helps interpret iron studies that would be misleading if read as simple deficiency. Its severity often tracks the underlying disease. This entry is descriptive and is not a basis for individual diagnosis or treatment.

Epidemiology

Anemia of chronic disease is regarded as among the most prevalent anemias overall and the most common in people with infection, autoimmune and inflammatory disorders, cancer, or chronic kidney disease (Weiss & Goodnough, 2005; Weiss et al., 2019). Its frequency rises with age and with the burden of chronic illness.

Evidence & guidelines

Authoritative reviews establish the inflammatory, hepcidin-centered understanding of the condition and its laboratory distinction from iron deficiency (Weiss & Goodnough, 2005; Ganz, 2019; Weiss et al., 2019). The mechanistic foundation rests on the demonstration that hepcidin controls iron efflux through ferroportin (Nemeth et al., 2004).

History

Long described as a poorly understood accompaniment of chronic illness, anemia of chronic disease was reconceived in the 2000s when hepcidin was identified as the master iron-regulatory hormone and shown to act on ferroportin, providing a unifying mechanism for inflammation-driven iron restriction. The condition is increasingly termed anemia of inflammation to reflect this mechanism.

Debates

Is 'anemia of chronic disease' the right name?

Because the defining process is inflammation rather than chronicity as such, many authors favor 'anemia of inflammation'; both terms remain in use and the relabeling reflects the hepcidin-centered mechanistic understanding.

How best to detect coexisting iron deficiency?

Inflammation raises ferritin and lowers serum iron, so simple iron studies can mask true iron deficiency; markers such as soluble transferrin receptor and hepcidin are proposed to separate the two states, but thresholds and assays are not fully standardized.

Key figures

• Guenter Weiss
• Tomas Ganz
• Elizabeta Nemeth
• Lawrence Tim Goodnough

Seminal works

• weiss-2005
• ganz-2019
• nemeth-2004

Frequently asked questions

Why are iron stores normal or high in anemia of chronic disease?

Inflammation raises hepcidin, which traps iron inside storage cells rather than releasing it to the marrow; total body iron is adequate (so ferritin is normal or high), but the iron is functionally unavailable for red-cell production.

Why is it increasingly called anemia of inflammation?

Because the underlying driver is immune activation and inflammatory signaling—chiefly through hepcidin—rather than chronicity itself, so 'anemia of inflammation' more accurately names the mechanism.